The immunogenetics of Psoriasis: A comprehensive review.
暂无分享,去创建一个
[1] Pui-Yan Kwok,et al. Genome-wide scan reveals association of psoriasis with IL-23 and NFB pathways , 2016 .
[2] A. Gottlieb,et al. Tildrakizumab (MK‐3222), an anti‐interleukin‐23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo‐controlled trial , 2015, The British journal of dermatology.
[3] H. Kittler,et al. Clinical improvement in psoriasis with specific targeting of interleukin-23 , 2015, Nature.
[4] X. Estivill,et al. Genome-wide meta-analysis identifies multiple novel associations and ethnic heterogeneity of psoriasis susceptibility , 2015, Nature Communications.
[5] A. Santos-Silva,et al. A specific molecular signature for psoriasis and eczema. , 2015, Annals of translational medicine.
[6] Liangdan Sun,et al. Whole-exome SNP array identifies 15 new susceptibility loci for psoriasis , 2015, Nature Communications.
[7] M. Hafner,et al. Laser capture microdissection followed by next‐generation sequencing identifies disease‐related microRNAs in psoriatic skin that reflect systemic microRNA changes in psoriasis , 2015, Experimental dermatology.
[8] Min Liu,et al. SRSF1 Facilitates Cytosolic DNA-Induced Production of Type I Interferons Recognized by RIG-I , 2015, PloS one.
[9] C. Wallace,et al. Dense genotyping of immune-related susceptibility loci reveals new insights into the genetics of psoriatic arthritis , 2015, Nature Communications.
[10] Wan-Wan Lin,et al. Syk mediates IL-17-induced CCL20 expression by targeting Act1-dependent K63-linked ubiquitination of TRAF6. , 2015, The Journal of investigative dermatology.
[11] C. Leonardi,et al. Humanized anti-IFN-γ (HuZAF) in the treatment of psoriasis. , 2015, The Journal of allergy and clinical immunology.
[12] A. Bowcock,et al. CARD14 Expression in Dermal Endothelial Cells in Psoriasis , 2014, PloS one.
[13] Sen Guo,et al. A single-nucleotide polymorphism of miR-146a and psoriasis: an association and functional study , 2014, Journal of cellular and molecular medicine.
[14] A. Pivarcsi,et al. Genetic polymorphisms altering microRNA activity in psoriasis – a key to solve the puzzle of missing heritability? , 2014, Experimental dermatology.
[15] Vinod Chandran,et al. Fine Mapping Major Histocompatibility Complex Associations in Psoriasis and Its Clinical Subtypes , 2014, American journal of human genetics.
[16] Y. Modis,et al. Pattern Recognition and Signaling Mechanisms of RIG-I and MDA5 , 2014, Front. Immunol..
[17] Fabian J Theis,et al. Intraindividual genome expression analysis reveals a specific molecular signature of psoriasis and eczema , 2014, Science Translational Medicine.
[18] M. Feolo,et al. HLA Diversity in the 1000 Genomes Dataset , 2014, PloS one.
[19] S. Ambs,et al. Tumor microenvironment-based feed-forward regulation of NOS2 in breast cancer progression , 2014, Proceedings of the National Academy of Sciences.
[20] Y. Wasfi,et al. Guselkumab (an IL-23-specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis. , 2014, The Journal of allergy and clinical immunology.
[21] F. Nestle,et al. The IL-23/IL-17 axis in psoriatic arthritis. , 2014, Autoimmunity reviews.
[22] Mayte Suárez-Fariñas,et al. Immunology of psoriasis. , 2014, Annual review of immunology.
[23] M. Schön,et al. c-Rel downregulation affects cell cycle progression of human keratinocytes. , 2014, The Journal of investigative dermatology.
[24] J. Blander,et al. Sensing Microbial RNA in the Cytosol , 2013, Front. Immunol..
[25] R. Henschler,et al. Aberrant epigenetic regulators control expansion of human CD34+ hematopoietic stem/progenitor cells , 2013, Frontiers in Genetics.
[26] S. Sano,et al. Epidermal hyperplasia induced by Raf-MAPK signaling requires Stat3 activation. , 2013, Journal of dermatological science.
[27] J. Schmid,et al. The complexity of NF-κB signaling in inflammation and cancer , 2013, Molecular Cancer.
[28] F. Abad‐Santos,et al. Gene polymorphisms that can predict response to anti-TNF therapy in patients with psoriasis and related autoimmune diseases , 2013, The Pharmacogenomics Journal.
[29] G. Vena,et al. Cyclosporine Regimens in Plaque Psoriasis: An Overview with Special Emphasis on Dose, Duration, and Old and New Treatment Approaches , 2013, TheScientificWorldJournal.
[30] J. Krueger,et al. IL-17 targeted therapies for psoriasis , 2013, Expert opinion on investigational drugs.
[31] K. Odunsi,et al. Induction and stability of human Th17 cells require endogenous NOS2 and cGMP-dependent NO signaling , 2013, The Journal of experimental medicine.
[32] C. Johansen,et al. Studies of Jak/STAT3 expression and signalling in psoriasis identifies STAT3‐Ser727 phosphorylation as a modulator of transcriptional activity , 2013, Experimental dermatology.
[33] Y. E. Chen,et al. Zc3h12c inhibits vascular inflammation by repressing NF-κB activation and pro-inflammatory gene expression in endothelial cells. , 2013, The Biochemical journal.
[34] P. Muranski,et al. Essentials of Th17 cell commitment and plasticity. , 2013, Blood.
[35] A. Gottlieb,et al. NF-κB: an essential transcription factor in psoriasis. , 2013, Journal of dermatological science.
[36] James T. Elder,et al. Identification of fifteen new psoriasis susceptibility loci highlights the role of innate immunity , 2012, Nature Genetics.
[37] W. Busse,et al. Genome-wide association studies of asthma indicate opposite immunopathogenesis direction from autoimmune diseases. , 2012, The Journal of allergy and clinical immunology.
[38] B. Aneskievich,et al. Emerging roles for TNIP1 in regulating post-receptor signaling. , 2012, Cytokine & growth factor reviews.
[39] A. Bowcock,et al. PSORS2 is due to mutations in CARD14. , 2012, American Journal of Human Genetics.
[40] James T. Elder,et al. Rare and common variants in CARD14, encoding an epidermal regulator of NF-kappaB, in psoriasis. , 2012, American journal of human genetics.
[41] Christian Gieger,et al. Combined analysis of genome-wide association studies for Crohn disease and psoriasis identifies seven shared susceptibility loci. , 2012, American journal of human genetics.
[42] A. Yoshimura,et al. SOCS, Inflammation, and Autoimmunity , 2011, Front. Immun..
[43] James T. Elder,et al. TNFAIP3 Gene Polymorphisms Are Associated with Response to TNF Blockade in Psoriasis , 2011, The Journal of investigative dermatology.
[44] Alan Menter,et al. A subset of methylated CpG sites differentiate psoriatic from normal skin , 2011, The Journal of investigative dermatology.
[45] Matti Pirinen,et al. Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity , 2012 .
[46] Anthony M Flores,et al. TNIP1 is a corepressor of agonist-bound PPARs. , 2011, Archives of biochemistry and biophysics.
[47] P. D. de Bakker,et al. Genome‐wide meta‐analysis identifies novel multiple sclerosis susceptibility loci , 2011, Annals of neurology.
[48] J. O’Shea,et al. Helper T-cell Differentiation and Plasticity: Insights from Epigenetics Introduction , 2022 .
[49] M. Simpson,et al. Mutations in IL36RN/IL1F5 are associated with the severe episodic inflammatory skin disease known as generalized pustular psoriasis. , 2011, American journal of human genetics.
[50] A. Smahi,et al. Interleukin-36-receptor antagonist deficiency and generalized pustular psoriasis. , 2011, The New England journal of medicine.
[51] C. Dong,et al. Signaling of interleukin-17 family cytokines in immunity and inflammation. , 2011, Cellular signalling.
[52] Richard C Trembath,et al. Functional analysis of the RNF114 psoriasis susceptibility gene implicates innate immune responses to double-stranded RNA in disease pathogenesis. , 2011, Human molecular genetics.
[53] D. de Ridder,et al. Narrowband ultraviolet B inhibits innate cytosolic double‐stranded RNA receptors in psoriatic skin and keratinocytes , 2011, The British journal of dermatology.
[54] K. Peris,et al. The IL23R R381Q Gene Variant Protects against Immune-Mediated Diseases by Impairing IL-23-Induced Th17 Effector Response in Humans , 2011, PloS one.
[55] P. Vito,et al. Alternative Splicing of CARMA2/CARD14 Transcripts Generates Protein Variants With Differential Effect on NF-κB Activation and Endoplasmic Reticulum Stress-Induced Cell Death , 2011, Journal of cellular physiology.
[56] Tomoki Chiba,et al. Interplay of transcription factors in T‐cell differentiation and function: the role of Runx , 2011, Immunology.
[57] Cisca Wijmenga,et al. A Meta-Analysis of Genome-Wide Association Scans Identifies IL18RAP, PTPN2, TAGAP, and PUS10 As Shared Risk Loci for Crohn's Disease and Celiac Disease , 2011, PLoS genetics.
[58] Xin Lin,et al. NF-κB signaling pathways regulated by CARMA family of scaffold proteins , 2011, Cell Research.
[59] P. Kwok,et al. Carriers of rare missense variants in IFIH1 are protected from psoriasis. , 2010, The Journal of investigative dermatology.
[60] R. Stephens,et al. Increased NOS2 predicts poor survival in estrogen receptor-negative breast cancer patients. , 2010, The Journal of clinical investigation.
[61] Christian Gieger,et al. Genome-wide association study identifies a psoriasis susceptibility locus at TRAF3IP2 , 2010, Nature Genetics.
[62] James T. Elder,et al. Association analyses identify six new psoriasis susceptibility loci in the Chinese population , 2010, Nature Genetics.
[63] Christian Gieger,et al. Common variants at TRAF3IP2 are associated with susceptibility to psoriatic arthritis and psoriasis , 2010, Nature Genetics.
[64] Matti Pirinen,et al. A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1 , 2010, Nature Genetics.
[65] Christian Gieger,et al. Genome-wide association analysis identifies three psoriasis susceptibility loci , 2010, Nature Genetics.
[66] S. Kotenko,et al. Interferon-lambda: a new addition to an old family. , 2010, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.
[67] Luis Puig,et al. Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditions. , 2010, The Journal of investigative dermatology.
[68] Jing Cui,et al. Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci , 2010, Nature Genetics.
[69] A. Blauvelt,et al. Circulating Th17, Th22, and Th1 cells are increased in psoriasis. , 2010, The Journal of investigative dermatology.
[70] James T. Elder,et al. Genome-wide association study identifies a psoriasis susceptibility locus at TRAF 3 IP 2 , 2010 .
[71] M. Daly,et al. Genetic variants at CD28, PRDM1, and CD2/CD58 are associated with rheumatoid arthritis risk , 2009, Nature Genetics.
[72] Ying Wang,et al. Genome-wide association study in a Chinese Han population identifies nine new susceptibility loci for systemic lupus erythematosus , 2009, Nature Genetics.
[73] A. Fisher,et al. Runx proteins regulate Foxp3 expression , 2009, The Journal of experimental medicine.
[74] T. Nomura,et al. Indispensable role of the Runx1-Cbfbeta transcription complex for in vivo-suppressive function of FoxP3+ regulatory T cells. , 2009, Immunity.
[75] M. Gilliet,et al. Self-RNA–antimicrobial peptide complexes activate human dendritic cells through TLR7 and TLR8 , 2009, The Journal of experimental medicine.
[76] A. Yoshimura. Regulation of cytokine signaling by the SOCS and Spred family proteins. , 2009, The Keio journal of medicine.
[77] F. Nestle,et al. The IL-23/Th17 axis in the immunopathogenesis of psoriasis. , 2009, The Journal of investigative dermatology.
[78] Lisa C. Zaba,et al. Resident and "inflammatory" dendritic cells in human skin. , 2009, The Journal of investigative dermatology.
[79] T. Mcclanahan,et al. The interleukin 23 receptor is essential for the terminal differentiation of interleukin 17–producing effector T helper cells in vivo , 2009, Nature Immunology.
[80] Wei Huang,et al. Psoriasis genome-wide association study identifies susceptibility variants within LCE gene cluster at 1q21 , 2009, Nature Genetics.
[81] Pui-Yan Kwok,et al. Genomewide Scan Reveals Association of Psoriasis with IL-23 and NF-κB Pathways , 2008, Nature Genetics.
[82] David Altshuler,et al. Genetic variants near TNFAIP3 on 6q23 are associated with systemic lupus erythematosus , 2008, Nature Genetics.
[83] B. Suarez-Alvarez,et al. NKG2D ligands: key targets of the immune response. , 2008, Trends in immunology.
[84] Yihong Yao,et al. Type I Interferon: Potential Therapeutic Target for Psoriasis? , 2008, PloS one.
[85] Stefan Jenisch,et al. Polymorphisms of the IL12B and IL23R genes are associated with psoriasis. , 2008, The Journal of investigative dermatology.
[86] L. van der Fits,et al. IFN-alpha enhances poly-IC responses in human keratinocytes by inducing expression of cytosolic innate RNA receptors: relevance for psoriasis. , 2008, The Journal of investigative dermatology.
[87] David S Sanders,et al. Newly identified genetic risk variants for celiac disease related to the immune response , 2008, Nature Genetics.
[88] M. Fu,et al. A Novel CCCH-Zinc Finger Protein Family Regulates Proinflammatory Activation of Macrophages* , 2008, Journal of Biological Chemistry.
[89] M. Leppert,et al. Variants in the 5q31 cytokine gene cluster are associated with psoriasis , 2008, Genes and Immunity.
[90] T. Michiels,et al. IFN-Lambda (IFN-λ) Is Expressed in a Tissue-Dependent Fashion and Primarily Acts on Epithelial Cells In Vivo , 2008, PLoS pathogens.
[91] S. Ghosh,et al. Shared Principles in NF-κB Signaling , 2008, Cell.
[92] Hua Yu,et al. Cutting Edge: An In Vivo Requirement for STAT3 Signaling in TH17 Development and TH17-Dependent Autoimmunity1 , 2007, The Journal of Immunology.
[93] T. Nomura,et al. Foxp3 controls regulatory T-cell function by interacting with AML1/Runx1 , 2007, Nature.
[94] James G. Krueger,et al. Pathogenesis and therapy of psoriasis , 2007, Nature.
[95] T. Imaizumi,et al. Cytokine modulation of retinoic acid-inducible gene-I (RIG-I) expression in human epidermal keratinocytes. , 2007, Journal of dermatological science.
[96] Anjana Rao,et al. Transcription factors T-bet and Runx3 cooperate to activate Ifng and silence Il4 in T helper type 1 cells , 2007, Nature Immunology.
[97] Steven J. Schrodi,et al. A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes. , 2007, American journal of human genetics.
[98] N. Perkins,et al. Integrating cell-signalling pathways with NF-kappaB and IKK function. , 2007, Nature reviews. Molecular cell biology.
[99] Pallavur Sivakumar,et al. Interleukin‐29 uses a type 1 interferon‐like program to promote antiviral responses in human hepatocytes , 2006, Hepatology.
[100] Antonio Leonardi,et al. ABIN-1 Binds to NEMO/IKKγ and Co-operates with A20 in Inhibiting NF-κB* , 2006, Journal of Biological Chemistry.
[101] James T. Elder. PSORS1: linking genetics and immunology. , 2006, The Journal of investigative dermatology.
[102] Antonio Leonardi,et al. ABIN-1 binds to NEMO/IKKgamma and co-operates with A20 in inhibiting NF-kappaB. , 2006, The Journal of biological chemistry.
[103] R. Steinman,et al. Increase in TNF-alpha and inducible nitric oxide synthase-expressing dendritic cells in psoriasis and reduction with efalizumab (anti-CD11a). , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[104] A. Bowcock. The genetics of psoriasis and autoimmunity. , 2005, Annual review of genomics and human genetics.
[105] A. Gottlieb,et al. Differential Expression of Phosphorylated NF-κB/RelA in Normal and Psoriatic Epidermis and Downregulation of NF-κB in Response to Treatment with Etanercept , 2005 .
[106] A. Gottlieb,et al. Differential expression of phosphorylated NF-kappaB/RelA in normal and psoriatic epidermis and downregulation of NF-kappaB in response to treatment with etanercept. , 2005, The Journal of investigative dermatology.
[107] A. Bowcock,et al. Psoriasis vulgaris: cutaneous lymphoid tissue supports T-cell activation and "Type 1" inflammatory gene expression. , 2004, Trends in immunology.
[108] Yudong D. He,et al. T lymphocyte activation gene identification by coregulated expression on DNA microarrays. , 2004, Genomics.
[109] L. van der Fits,et al. In psoriasis lesional skin the type I interferon signaling pathway is activated, whereas interferon-alpha sensitivity is unaltered. , 2004, The Journal of investigative dermatology.
[110] Jurg Ott,et al. A putative RUNX1 binding site variant between SLC9A3R1 and NAT9 is associated with susceptibility to psoriasis , 2003, Nature Genetics.
[111] R. Rottapel,et al. Regulation of cytokine receptor signaling by SOCS1 , 2003, Immunological reviews.
[112] Mark Lebwohl,et al. Psoriasis , 1906, The Lancet.
[113] T. Mcclanahan,et al. A Receptor for the Heterodimeric Cytokine IL-23 Is Composed of IL-12Rβ1 and a Novel Cytokine Receptor Subunit, IL-23R1 , 2002, The Journal of Immunology.
[114] G. Krueger,et al. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. , 2001, The New England journal of medicine.
[115] M. Nevalainen,et al. Increased expression of cyclooxygenase-2 and nitric oxide synthase-2 in human prostate cancer , 2001, Urological Research.
[116] J Wagner,et al. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. , 2000, Immunity.
[117] R. Contreras,et al. The Zinc Finger Protein A20 Inhibits TNF-induced NF-κB–dependent Gene Expression by Interfering with an RIP- or TRAF2-mediated Transactivation Signal and Directly Binds to a Novel NF-κB–inhibiting Protein ABIN , 1999, The Journal of cell biology.
[118] U. Engelmann,et al. Selective expression of inducible nitric oxide synthase in human prostate carcinoma , 1998, Cancer.
[119] U. Gubler,et al. Differential Associations between the Cytoplasmic Regions of the Interleukin-12 Receptor Subunits β1 and β2 and JAK Kinases* , 1997, The Journal of Biological Chemistry.
[120] U. Gubler,et al. Differential associations between the cytoplasmic regions of the interleukin-12 receptor subunits beta1 and beta2 and JAK kinases. , 1997, The Journal of biological chemistry.
[121] James G. Krueger,et al. Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis , 1995, Nature Genetics.
[122] P. Itin,et al. The type I interferon system is locally activated in psoriatic lesions. , 1994, Journal of interferon research.
[123] K. Wuepper,et al. Psoriasis vulgaris: a genetic approach. , 1990, The Journal of investigative dermatology.
[124] L. Nanney,et al. Altered [125I]epidermal growth factor binding and receptor distribution in psoriasis. , 1986, The Journal of investigative dermatology.
[125] W. Mueller,et al. Cyclosporin A for psoriasis. , 1979, The New England journal of medicine.